Optimizing the use of carbapenems in the face of i...[Crit Care. 2008]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Crit Care. 2008;12 Suppl 4:S1. Epub 2008 May 21. Links

Optimizing the use of carbapenems in the face of increasing Gram-negative resistance.

Ramphal R.

Division of Infectious Diseases, Department of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA. ramphr@medicine.efl.edu

PMID: 18495058 [PubMed - indexed for MEDLINE]

PMCID: PMC2391263

ReviewThe role of carbapenems in initial therapy for serious Gram-negative infections.
Crit Care. 2008; 12 Suppl 4:S5. Epub 2008 May 21.

[Crit Care. 2008]
ReviewBeta-lactam resistance in the gram negatives: increasing complexity of conditional, composite and multiply resistant phenotypes.
Pathology. 2006 Dec; 38(6):498-506.

[Pathology. 2006]
Utilization rate of carbapenems at intensive care units is not major determinant of gram-negative bacteria resistance to these antibiotics.
J Infect. 2007 Nov; 55(5):480-1. Epub 2007 Aug 31.

[J Infect. 2007]
ReviewMultidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
Curr Opin Investig Drugs. 2008 Feb; 9(2):176-83.

[Curr Opin Investig Drugs. 2008]
Screening for antibiotic resistant Gram-negative bacteria.
Lancet Infect Dis. 2006 Jun; 6(6):316-7.

[Lancet Infect Dis. 2006]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

Optimizing the use of carbapenems in the face of increasing Gram-negative resistance.Optimizing the use of carbapenems in the face of increasing Gram-negative resistance.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show

Optimizing the use of carbapenems in the face of increasing Gram-negative resistance.

Related articles

Recent Activity